Generative AI Education Tool for Breast Cancer Care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study examines a retrieval-augmented generation AI tool, OpenEvidence CareConnect, designed to provide general and breast cancer–specific information to patients. The lead-in phase assesses safety in metastatic breast cancer patients, followed by a randomized phase comparing immediate access versus waitlist control. Outcomes include the tool’s accuracy, usefulness, and impact on patient-provider communication, with surveys and provider assessments throughout. Eligible participants include adults with Stage IV or recent Stage I–III breast cancer, who have computer access and can consent. The trial is conducted at UCSF and affiliated sites with a 5-participant lead-in followed by 30 randomized participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Females or males ages 18 and over.
2. Patients must have either:

   1. Stage IV breast cancer facing a treatment change and are expected to have follow-up visits at least once every three months, or
   2. Stage I-III breast cancer diagnosed within the past 6 months.
3. Basic computer literacy and regular internet access at home.
4. Able to understand study procedures and to comply with them for the entire length of the study.
5. Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

1. Contraindication to any study-related procedure or assessment.
2. Cognitive impairment that would interfere with tool usage or survey completion

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Michelle Melisko, MD — University of California, San Francisco
• Study coordinator: Ivy Ow
• Email: Ivy.Wong@ucsf.edu
• Phone: 877-827-3222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• UGT1A1 gene and side effects from certain antibody-drug treatments for advanced breast cancer

  This project will test whether common UGT1A1 gene variants explain who gets worse side effects from antibody-drug conjugates (sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan) in adults with advanced breast cancer.

  Recruiting Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Granada, Granada · NCT07582887

• Pulsed Electric Field Ablation for Metastatic Breast Cancer

  This trial tests a one-time pulsed electric field ablation to treat superficial metastatic breast cancer lesions in adults, guided by imaging.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07487844

• Adaptive biomarker-driven therapies for metastatic breast cancer

  This trial tests whether matching targeted drug combinations to tumor biomarkers helps people with ER+/HER2- or triple-negative metastatic breast cancer who are starting second-line treatment.

  Recruiting at 4 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · New Haven, Connecticut and 5 other locations · NCT07340541

• Increasing exercise for people with metastatic breast cancer using the Get Real and Heel program

  This project will try offering the Get Real and Heel (GRH) exercise program to people with metastatic breast cancer at UNC to see if it increases physical activity and improves symptoms and quality of life.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07313306

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.